Literature DB >> 16476098

Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.

C D Thornburg, S W Pipe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16476098     DOI： 10.1111/j.1365-2516.2006.01172.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  8 in total

1.  Physician trust and depression influence adherence to factor replacement: a single-centre cross-sectional study.

Authors:  D Q Tran; V Barry; A Antun; M Ribeiro; S Stein; C L Kempton
Journal:  Haemophilia       Date:  2016-09-30       Impact factor: 4.287

2.  Validation of the VERITAS-Pro treatment adherence scale in a Spanish sample population with hemophilia.

Authors:  Rubén Cuesta-Barriuso; Ana Torres-Ortuño; Pilar Galindo-Piñana; Joaquín Nieto-Munuera; Natalie Duncan; José Antonio López-Pina
Journal:  Patient Prefer Adherence       Date:  2017-03-27       Impact factor: 2.711

Review 3.  Treatment adherence in hemophilia.

Authors:  Courtney D Thornburg; Natalie A Duncan
Journal:  Patient Prefer Adherence       Date:  2017-09-27       Impact factor: 2.711

4.  Validation of the Brazilian version of the VERITAS-Pro scale to assess adherence to prophylactic regimens in hemophilia.

Authors:  Adriana Aparecida Ferreira; Isabel Cristina Gonçalves Leite; Natalie August Duncan
Journal:  Rev Bras Hematol Hemoter       Date:  2017-11-26

5.  Patient and parent preferences for characteristics of prophylactic treatment in hemophilia.

Authors:  Roberto Furlan; Sangeeta Krishnan; Jeffrey Vietri
Journal:  Patient Prefer Adherence       Date:  2015-11-23       Impact factor: 2.711

6.  Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A.

Authors:  Jayashree Motwani; Benoit Guillet; Jan Blatny; Freimut H Schilling; Bénédicte Wibaut; Jimena Goldstine; Andras Nagy; Jennifer Doralt; Werner Engl; Srilatha Tangada; Gerald Spotts
Journal:  Haemophilia       Date:  2020-04-27       Impact factor: 4.287

Review 7.  GlycoPEGylated recombinant factor IX for hemophilia B in context.

Authors:  Elena Santagostino; Maria Elisa Mancuso
Journal:  Drug Des Devel Ther       Date:  2018-09-11       Impact factor: 4.162

8.  Hemophilia prophylaxis adherence and bleeding using a tailored, frequency-escalated approach: The Canadian Hemophilia Primary Prophylaxis Study.

Authors:  Saunya Dover; Victor S Blanchette; Darius Wrathall; Eleanor Pullenayegum; Daniel Kazandjian; Byron Song; Sue Ann Hawes; Stéphanie Cloutier; Geroges E Rivard; Robert J Klaassen; Elizabeth Paradis; Nicole Laferriere; Ann Marie Stain; Anthony K Chan; Sara J Israels; Roona Sinha; MacGregor Steele; John K M Wu; Brian M Feldman
Journal:  Res Pract Thromb Haemost       Date:  2020-01-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.